Comparing YSQTG to placebo with standard treatment for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an herbal granule (YSQTG) to standard chemotherapy with or without immunotherapy helps patients with a specific type of advanced esophageal cancer. It focuses on people whose cancer is stage III to IVa and who have not had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell esophageal cancer that is stage III to IVa and can be removed with surgery.
- You have not had any previous treatment for this cancer.
- You are between 18 and 80 years old.
- You have a Karnofsky score of 70 or higher (able to care for most daily needs).
- You have symptoms that match a particular traditional Chinese medicine pattern called 'kidney deficiency with blood stasis and toxin stagnation'.
- You do not have other serious illnesses, other cancers, or allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests a Chinese herbal formula (YSQTG) combined with standard immunotherapy and chemotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding YSQTG improves outcomes for patients with a specific traditional Chinese medicine pattern.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.